item1.txt
Certain of the Company’s facility leases contain options to renew or extend the terms of the lease which are included in the determination of the ROU assets and lease liabilities when it is reasonably certain that the Company will exercise the option.
The Company's leases may also include variable lease payments such as an escalation clause based on consumer price index rates, maintenance costs and utilities.
At September 27, 2019, the Company did not have any lease agreements with residual value guarantees.
The related lease payments on the Company’s short-term facilities and equipment leases are recognized as expense on a straight-line basis over the lease term.
Option periods are included in the lease term if the Company determines that it is reasonably certain the customer will exercise an option.
If the Company accounts for an arrangement both as a lease and non-lease component, then the allocation of consideration for each component will be based the relative standalone sales price.
The Company includes outstanding payments within "Cash and cash equivalents" and correspondingly increases "Accounts payable and accrued liabilities" on the condensed consolidated balance sheets.
At September 27, 2019 and December 28, 2018, the Company included $33 million and $56 million, respectively, of outstanding payments within "Cash and cash equivalents."
The Company will occupy the space for an initial term of 148 months and rent expense will be $11 million for the first lease year, with an annual rent expense increase of 2.5%.
During the quarter and nine months ended September 28, 2018, the Company had $40 million and $120 million of net rental expense, respectively.
As of September 27, 2019, the Company had a total net investment in sales-type leases, which relates to lease payment receivables, of $56 million.
The current and non-current portions of net investment in sales-type leases are included within "Other current assets" and "Other assets", respectively, on the Company's consolidated balance sheets.
Revenue recognized for the quarter and nine months ended September 27, 2019 of $11 million and $200 million, respectively, was included as a contract liability at December 28, 2018.
Revenue recognized for the quarter and nine months ended September 28, 2018 of $37 million and $164 million, respectively, was included as a contract liability at December 30, 2017 (date of adoption).
On August 15, 2019, the Company completed the acquisition of IMX Medical Management Services, Inc. and its affiliated businesses ("IMX") for preliminary purchase consideration of $95 million, which primarily included $90 million of cash paid and an additional $4 million paid to extinguish IMX's existing term loans and credit facility balances.
The Company recorded $51 million of goodwill (which is deductible for tax purposes) and $42 million of intangible assets.
In February 2019, the Company received initial proceeds of $171 million.
The Company recorded a pre-tax gain on sale of $87 million, net of assets divested of $69 million and $10 million in transaction related costs.
The Company received proceeds of $31 million, net of selling costs for the property, which had a carrying value of $31 million.
On December 28, 2018, the Company closed the sale and leaseback agreement relating to two buildings and the adjacent land in San Diego, CA for consideration of $79 million, net of selling costs.
The Company received cash proceeds of $14 million upon closing in December 2018, and received the remaining $65 million cash proceeds in January 2019.
The Company's derivatives consisted of the fair value interest rate swaps on its $450 million, fixed rate 4.45% senior secured notes maturing in December 2020 and cash flow interest rate swaps on $1.5 billion of the Company's variable rate senior secured term loans (see "Note 13–Derivative Instruments").
The carrying amounts of the Company's financial instruments, other than derivatives, which include cash equivalents, accounts receivable, accounts payable and accrued expenses, are reasonable estimates of their related fair values.
The carrying value of the Company's note receivable of $25 million and $24 million as of September 27, 2019, and December 28, 2018, respectively, approximates fair value as the stated interest rate within the agreement is consistent with current market rates used in notes with similar terms in the market (Level 2 inputs).
The fair value of long-term debt is determined based on current interest rates available for debt with terms and maturities similar to the Company’s existing debt arrangements (Level 2 inputs).
On August 15, 2019, the Company recorded non-financial instruments measured at fair value on a non-recurring basis in connection with the acquisition of IMX (see "Note 7–Acquisitions").
As of September 27, 2019, the Company did not have any assets or liabilities measured at fair value on a non-recurring basis.
The Company has interest rate swap agreements to hedge the fair value of the $450 million fixed rate 4.45% senior secured notes maturing in December 2020 (the "Notes").
Under the terms of the interest rate swap agreements, the Company will receive semi-annual interest payments at the coupon rate of 4.45% and will pay variable interest based on the six-month LIBOR rate.
The Company made principal payments on its long-term debt of $2 million and $50 million during the quarter and nine months ended September 27, 2019, respectively, and $15 million and $59 million during the quarter and nine months ended September 28, 2018, respectively.
This activity included principal payments on its senior secured term loans of $41 million during the nine months ended September 27, 2019 and $15 million and $46 million during the quarter and nine months ended September 28, 2018, respectively.
There were no principal payments on the Company's senior secured term loans for the quarter ended September 27, 2019.
In April 2018, the Company made a required debt prepayment of $10 million on its senior secured term loans.
Amortization of the debt discount and deferred debt issuance costs related to the senior secured term loans and notes, unsecured notes and revolving credit facility was $2 million and $7 million for the quarter and nine months ended September 27, 2019, respectively, and $2 million and $8 million for the quarter and nine months ended September 28, 2018, respectively.
During the quarter ended March 29, 2019, the Company paid $200 million to the financial institution and received an initial delivery of 2.6 million shares.
In April 2019, the Company received the final delivery of 0.6 million shares related to the ASR agreement.
During the quarter ended September 27, 2019, the Company paid $200 million to the financial institution and received 2.4 million shares related to the ASR agreement.
The total number of shares that the Company received under the ASR agreement was based on the volume-weighted-average-price of $84.25 per share for the period August 1, 2019 to September 25, 2019.
During the quarter and nine months ended September 28, 2018, the Company made open market repurchases of its common stock for an aggregate purchase price of $62 million and $162 million, respectively.
See "Note 4–Leases" for additional supplementary cash flow information related to the Company's leases.
The restricted cash is recorded within "Other current assets" in the Company's condensed consolidated balance sheets.
On September 10, 2019, the Company received $59 million on behalf of Leidos and its subcontractors, substantially, though not entirely, resolving the Company’s claim.
The Company does not have any assets or liabilities recorded in connection with this matter as of September 27, 2019.
On September 30, 2019, the Company paid its $48 million dividend for the quarter ended September 27, 2019.


item2.txt
The increase in revenues for the nine months ended September 27, 2019, as compared to the nine months ended September 28, 2018, was primarily attributable to new awards and a net increase in program volumes, partially offset by the completion of certain contracts, lower net profit write-ups in the current year and adverse exchange rate movements in the Australian dollar when compared to the U.S. dollar.
The increase in operating income for the three months ended September 27, 2019, as compared to the three months ended September 28, 2018, was primarily due to new awards and favorable program mix, partially offset by lower net profit write-ups in the current quarter.
The increase in operating income for the nine months ended September 27, 2019, as compared to the nine months ended September 28, 2018, was primarily due to new awards and lower amortization of intangibles, partially offset by lower net profit write-ups in the current year.
The increase in revenues for the three months ended September 27, 2019, as compared to the three months ended September 28, 2018, was primarily attributable to new awards and a net increase in program volumes, partially offset by the impact of the sale of our commercial cybersecurity business and lower net profit write-ups in the current quarter.
The increase in revenues for the nine months ended September 27, 2019, as compared to the nine months ended September 28, 2018, was primarily attributable to new awards and a net increase in program volumes, partially offset by the impact of the sale of our commercial cybersecurity business, the completion of certain contracts, lower net profit write-ups in the current year and adverse exchange rate movements in the British pound when compared to the U.S. dollar.
The decrease in operating income for the nine months ended September 27, 2019, as compared to the nine months ended September 28, 2018, was primarily due to lower net profit write-ups in the current year and increased bad debt expense on certain international contracts, partially offset by lower amortization of intangibles and new awards.
The increase in revenues for the three and nine months ended September 27, 2019, as compared to the three and nine months ended September 28, 2018, was primarily attributable to a net increase in program volumes and new awards, partially offset by the completion of certain contracts and the impact of the sale of our health staff augmentation business.
Net cash provided by operating activities decreased $22 million for the three months ended September 27, 2019, when compared to the prior year quarter, primarily due to $60 million of proceeds received from the termination of interest rates swaps in the prior year quarter, the prefunding of our quarterly dividend and higher tax payments.
Net cash provided by operating activities increased $159 million for the nine months ended September 27, 2019, when compared to the prior year, primarily due to more favorable timing of working capital changes, $59 million received for the Greek arbitration award, lower payments for integration and restructuring costs and $24 million of cash paid in the prior year related to our 2016 acquisition.
Net cash used in investing activities increased $117 million for the three months ended September 27, 2019, when compared to the prior year quarter, primarily due to $94 million of cash paid related to the acquisition of IMX and $40 million of proceeds received from the settlement of a promissory note in the prior year quarter, partially offset by $12 million of net proceeds received for the divestiture of our health staff augmentation business.
Net cash provided by investing activities increased $213 million for the nine months ended September 27, 2019, when compared to the prior year, primarily due to $183 million of proceeds received for the dispositions of our commercial cybersecurity and health staff augmentation businesses, $96 million of proceeds received for the sale of real estate properties and $81 million of cash paid in the prior year related to our 2016 acquisition.
Net cash used in financing activities increased $70 million for the three months ended September 27, 2019, when compared to the prior year quarter, primarily due to a $137 million increase in stock repurchases, partially offset by the timing of dividend and debt payments.


item4.txt
Item 4.


part2.txt
Unregistered Sales of Equity Securities and Use of Proceeds.
Defaults Upon Senior Securities.


